What is the recommended treatment regimen for Bowen's disease of the skin using imiquimod (immune response modifier)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 2, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The recommended treatment regimen for Bowen's disease using imiquimod typically involves applying 5% imiquimod cream to the affected area once daily, 5 days per week, for a period of 6-16 weeks, as supported by the most recent and highest quality study 1.

Key Considerations

  • The treatment duration depends on clinical response, with regular follow-up evaluations recommended to assess efficacy and manage side effects.
  • Patients should expect local skin reactions including redness, swelling, erosion, and crusting as these indicate the desired immune response is occurring.
  • These reactions typically peak after 2-4 weeks of treatment.
  • Imiquimod works by stimulating the innate immune system through Toll-like receptor 7, producing cytokines that promote a cell-mediated immune response against abnormal cells.

Treatment Application

  • The cream should be applied to clean, dry skin, covering the lesion and a small margin of surrounding normal skin.
  • It should remain on the skin for 8 hours before being washed off with mild soap and water.

Patient Selection

  • This treatment is particularly useful for patients with multiple or large lesions, those in cosmetically sensitive areas, or individuals who are poor surgical candidates.
  • Treatment should be temporarily suspended if severe local skin reactions develop, resuming once the reaction subsides, as noted in earlier guidelines 1 and further supported by later studies 1.

Evidence Base

  • The evidence base for imiquimod in treating Bowen's disease includes small randomized trials and open studies, with the most significant support coming from a study demonstrating 73% histologically proven resolution with imiquimod versus zero response in the placebo group 1.
  • Later guidelines continue to support the use of imiquimod, although they also highlight the need for further investigation into the ideal dosing regimen and cost-effectiveness 1.

From the Research

Imiquimod Treatment for Bowen's Disease

  • The recommended dose of imiquimod for treating Bowen's disease of the skin is 5% cream, applied topically 2, 3, 4, 5.
  • The treatment regimen varies, with some studies using once-daily self-application for 16 weeks 3, while others use a cycle regimen of three times weekly for 3 weeks followed by a 4-week rest period 5.
  • Imiquimod 5% cream has been shown to be an effective treatment for Bowen's disease, with a positive treatment response in 93% of biopsy-proven cases 3 and complete clinicopathologic regression in 80% of lesions 4.
  • However, the recurrence rate for imiquimod treatment has been reported to be as high as 33.33% 6, highlighting the need for careful monitoring and follow-up.

Treatment Outcomes

  • Studies have reported successful treatment of Bowen's disease with imiquimod 5% cream, with no residual tumor present in post-treatment biopsy specimens in 93% of cases 3.
  • Imiquimod treatment has also been shown to reverse the CD4/CD8 lymphocyte ratio in post-treatment biopsy specimens, indicating a shift in the immune response 3.
  • The treatment period for imiquimod has been reported to be longer than other treatment modalities, such as surgical excision and photodynamic therapy 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.